CONCLUSION
PDAC
Abemaciclib monotherapy or in combination with the PI3K/mTOR inhibitor LY3023414 did not improve DCR, PFS, or OS compared to standard chemotherapy in pretreated metastatic PDAC.Given the aggressive nature of metastatic PDAC, molecularly guided interventions will need to account for complex signaling pathways and select biomarkers to identify patients most likely to benefit.